AR068794A1 - Compuestos antivirales - Google Patents

Compuestos antivirales

Info

Publication number
AR068794A1
AR068794A1 ARP080102758A ARP080102758A AR068794A1 AR 068794 A1 AR068794 A1 AR 068794A1 AR P080102758 A ARP080102758 A AR P080102758A AR P080102758 A ARP080102758 A AR P080102758A AR 068794 A1 AR068794 A1 AR 068794A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
alkynyl
alkenyl
och2p
Prior art date
Application number
ARP080102758A
Other languages
English (en)
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AR068794A1 publication Critical patent/AR068794A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Compuestos antivirales, composiciones que contienen tales compuestos y uso de los compuestos para preparar medicamentos utiles para tratar la hepatitis C. Reivindicacion 1: Un compuesto de formula (1) o su sal, o profármaco aceptable para uso farmacéutico, donde R1 se selecciona independientemente H, alquilo, alquenilo, alquinilo, arilo, cicloalquilo, heterociclo, halogeno, haloalquilo, alquilsulfonamido, arilsulfonamido, -C(O)NHS(O)2-, o -S(O)2-, opcionalmente sustituido con uno o más A3; R2 se selecciona de, a) -C(Y1)(A3), b) alquilo C2-10, cicloalquilo C3-7 o alquilo C1-4-cicloalquilo C3-7, donde dicho cicloalquilo y alquil-cicloalquilo puede estar opcionalmente mono-, di-o tri-sustituido con alquilo C1-3, o donde dicho alquilo, cicloalquilo y alquil-cicloalquilo puede estar opcionalmente mono- o di-sustituido con sustituyentes seleccionados de hidroxi y O-alquilo C1-4, o donde cada uno de dichos grupos alquilo puede estar opcionalmente mono-, di- o tri-sustituido con halogeno, o donde cada uno de dichos grupos cicloalquilo tiene 5, 6 o 7 miembros, uno o dos -CH2- grupos no está directamente enlazado uno con otro puede estar opcionalmente reemplazado por -O- de modo que el átomo O está enlazado al átomo N al cual R2 está unido mediante al menos dos átomos C, c) fenilo, alquilo C1-3-fenilo, heteroarilo o alquilo C1-3-heteroarilo, donde los grupos heteroarilo son de 5 o 6 miembros que tienen de 1 hasta 3 heteroátomos seleccionados de N, O y S, donde dichos grupos fenilo y heteroarilo pueden estar opcionalmente mono-, di- o trisustituido con sustituyentes seleccionados de halogeno, -OH, alquilo C1-4, O-alquilo C1-4, S-alquilo C1-4, -NH2, -CF3, -NH(alquilo C1-4) y -N(alquilo C1-4)2, -CONH2 y -CONH-alquilo C1-4; y donde dicho alquilo C1-3 puede estar opcionalmente sustituido con uno o más halogeno; d) -S(O)2(A3); o e) -C(Y1)-X-Y; R3 es H o alquilo C1-6; Y1 es independientemente O, S, N(A3), N(O)(A3), N(OA3), N(O)(OA3) o N(N(A3)(A3)); Z es O, S, o NR3; Z1 es un grupo orgánico que tiene una forma tridimensional que se adaptará a la region S2 extendida del dominio de la NS3 serina proteasa del VHC; Z2b es H, alquilo C1-10, alquenilo C2-10, alquinilo C2-10; Q1 es A3; o Q1 y Z2a tomados juntos con los átomos a los cuales están unidos forman un heterociclo, dicho heterociclo puede estar opcionalmente sustituido con uno o más oxo (=O), R4, o A3; cada X es independientemente un enlace, O, S, o NR3; Y es un policarbociclo o un poliheterociclo, dicho policarbociclo o un poliheterociclo está opcionalmente sustituido con uno o más R4, halo, carboxi, hidroxi, alquilo C1-10, alquenilo C2-10, alquinilo C2-10, alcanoilo C1-10, alcoxi C1-10, alcanoiloxi C1-10, alcoxi C1-10carbonilo, NRnRp, SRr, S(O)Rr, o S(O)2Rr; cada R4 es independientemente -P(Y3)(OA2)(OA2), -P(Y3)(OA2)(N(A2)2), -P(Y3)(A2)(OA2), -P(Y3)(A2)(N(A2)2), o P(Y3)(N(A2)2)(N(A2)2); cada Y es independientemente O, S, o NR3; cada Rn y Rp es independientemente H, alquilo C1-10, alquenilo C2-10, alquinilo C2-10, alcanoilo C1-10, alcoxi C1-10, alcanoiloxi C1-10, o alcoxi C1-10carbonilo, dicho alquilo C1-10, alquenilo C2-10, alquinilo C2-10, alcanoilo C1-10, alcoxi C1-10, alcanoiloxi C1-10, o alcoxi C1-10carbonilo, está opcionalmente sustituido con uno o más R4, halo, hidroxi, carboxi, ciano, o alcoxi C1-10; o Rn y Rp juntos con el nitrogeno al cual están unidos forman un anillo pirrolidina, piperidina, piperazina, morfolino o tiomorfolino; cada Rr es independientemente H, alquilo C1-10, alquenilo C2-10, alquinilo C2-10, alcanoilo C1-10, o alcoxi C1-10carbonilo; Z2a es H, alquilo C1-10, alquenilo C2-10, alquinilo C2-10, haloalquilo, C1-10alquil-S(=O)2-alquilo C1-10, o cicloalquilo, donde cualquier átomo de carbono de Z2a puede estar opcionalmente reemplazado con un heteroátomo seleccionado de O, S, S(=O), S(=O)2, o N y donde cualquier cicloalquilo está opcionalmente sustituido con uno o más alquilo C1-10, alquenilo C2-10, alquinilo C2-10, haloalquilo, F, CI, Br, o l; o Z2a opcionalmente forma un heterociclo con uno o más R1, R2, Q1, o A3; A3 se selecciona independientemente PRT, H, -OH, -C(O)OH, ciano, alquilo, alquenilo, alquinilo, amino, amido, imido, mino, halogeno, CF3, CH2CF3, cicloalquilo, nitro, arilo, aralquilo, alcoxi, ariloxi, heterociclo, -C(A2)3, -C(A2)2-C(O)A2, -C(O)A2, -C(O)OA2, -O(A2), -N(A2)2, -S(A2), -CH2P(Y1)(A2)(OA2), -CH2P(Y1)(A2)(N(A2)2), -CH2P(Y1)(OA2)(OA2), -OCH2P(Y1)(OA2)(OA2), -OCH2P(Y1)(A2)(OA2), -OCH2P(Y1)(A2)(N(A2)2), -C(O)OCH2P(Y1)(OA2)(OA2), -C(O)OCH2P(Y1)(A2)(OA2), -C(O)OCH2P(Y1)(A2)(N(A2)2), -CH2P(Y1)(OA2)(N(A2)2), -OCH2P(Y1)(OA2)(N(A2)2), -C(O)OCH2P(Y1)(OA2)(N(A2)2), -CH2P(Y1)(N(A2)2)(N(A2)2), -C(O)OCH2P(Y1)(N(A2)2)(N(A2)2), -OCH2P(Y1)(N(A2)2)(N(A2)2), (CH2)m-heterociclo, -(CH2)mC(O)O-alquilo, -O-(CH2)m-O-C(O)-O-alquilo, -O-(CH2)r-O-C(O)-(CH2)m-alquilo, -(CH2)mO-C(O)-O-alquilo, -(CH2)m-OC(O)O-cicloalquilo, -N(H)C(Me)C(O)O-alquilo, SRr, S(O)Rr, S(O)2Rr, o alcoxi arilsulfonamida, donde cada A3 puede estar opcionalmente sustituido con 1 hasta 4 -R1, -P(Y1)(OA2)(OA2), -P(Y1)(OA2)(N(A2)2), -P(Y1)(A2)(OA2), -P(Y1)(A2)(N(A2)2), o P(Y1)(N(A2)2)(N(A2)2), -C(=O)N(A2)2), halogeno, alquilo, alquenilo, alquinilo, arilo, carbociclo, heterociclo, aralquilo, arilo sulfonamida, arilo alquilsulfonamida, ariloxi sulfonamida, ariloxi alquilsulfonamida, ariloxi arilsulfonamida, alquilo sulfonamida, alquiloxisulfonamida, alquiloxi alquilsulfonamida, ariltio, -(CH2)m-heterociclo, -(CH2)m-C(O)O-alquilo, -O(CH2)mOC(O)O-alquilo, -O-(CH2)m-OC(O)-(CH2)m-alquilo, -(CH2)m-O-C(O)-O-alquilo, -(CH2)m-O-C(O)-O-cicloalquilo, -N(H)C(CH3)C(O)O-alquilo, o alcoxi arilsulfonamida, opcionalmente sustituido con R1; opcionalmente cada instancia independiente de A3 y Q1 pueden ser tomados juntos con uno o más A3 o Q1 grupos para formar un anillo; y A2 se selecciona independientemente PRT, H, alquilo, alquenilo, alquinilo, amino, aminoácido, alcoxi, ariloxi, ciano, haloalquilo, cicloalquilo, arilo, heteroarilo, heterociclo, alquilsulfonamida, o arilsulfonamida, donde cada A2 está opcionalmente sustituido con A3; Rf es A3; y m es 0 hasta 6; siempre que el compuesto de formula (1) no sea el compuesto de la formula (2).
ARP080102758A 2007-06-29 2008-06-26 Compuestos antivirales AR068794A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93775207P 2007-06-29 2007-06-29
US95969807P 2007-07-16 2007-07-16

Publications (1)

Publication Number Publication Date
AR068794A1 true AR068794A1 (es) 2009-12-09

Family

ID=40202103

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102758A AR068794A1 (es) 2007-06-29 2008-06-26 Compuestos antivirales

Country Status (19)

Country Link
US (2) US8513186B2 (es)
EP (1) EP2162432A2 (es)
JP (2) JP5465667B2 (es)
KR (1) KR20100038417A (es)
CN (1) CN101801925A (es)
AP (1) AP2009005073A0 (es)
AR (1) AR068794A1 (es)
AU (1) AU2008271117B2 (es)
BR (1) BRPI0813733A2 (es)
CA (1) CA2692145C (es)
CO (1) CO6251241A2 (es)
EA (1) EA200971074A1 (es)
EC (1) ECSP109906A (es)
IL (1) IL202623A0 (es)
MX (1) MX2009013830A (es)
SG (1) SG182979A1 (es)
TW (1) TW200914013A (es)
WO (1) WO2009005677A2 (es)
ZA (1) ZA201000614B (es)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
RU2008152171A (ru) 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
ES2437147T3 (es) * 2008-02-04 2014-01-09 Idenix Pharmaceuticals, Inc. Inhibidores de serina proteasa macrocíclicos
US20090285773A1 (en) * 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
KR20110054003A (ko) 2008-09-17 2011-05-24 베링거 인겔하임 인터내셔날 게엠베하 Ｈｃｖ ｎｓ3 프로테아제 억제제와 인터페론 및 리바비린의 병용물
EP2344487A4 (en) * 2008-09-23 2012-03-21 Boehringer Ingelheim Int HEPATITIS C INHIBITOR COMPOUNDS
CN102300871A (zh) * 2008-12-19 2011-12-28 吉里德科学公司 Hcv ns3蛋白酶抑制剂
US20100196321A1 (en) * 2009-01-30 2010-08-05 Glaxosmithkline Llc Compounds
JP2012520891A (ja) * 2009-03-19 2012-09-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング スルホニルキノリンの製造方法
TW201040181A (en) 2009-04-08 2010-11-16 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
KR20120026024A (ko) 2009-04-24 2012-03-16 가부시키가이샤 가네카 Ｎ-알콕시카르보닐-ｔｅｒｔ-류신의 제조법
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
TW201109335A (en) 2009-08-04 2011-03-16 Takeda Pharmaceutical Heterocyclic compounds
WO2011017389A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
CA2775697A1 (en) * 2009-09-28 2011-03-31 Intermune, Inc. Cyclic peptide inhibitors of hepatitis c virus replication
KR20120110090A (ko) * 2009-09-28 2012-10-09 에프. 호프만-라 로슈 리미티드 Ｃ형 간염 바이러스 복제의 신규한 마크로시클릭 저해제
KR20120106942A (ko) 2009-10-30 2012-09-27 베링거 인겔하임 인터내셔날 게엠베하 Ｂｉ２０１３３５, 인터페론 알파 및 리바비린을 포함하는 ｈｃｖ 병용 치료요법을 위한 투여 용법
WO2011061679A1 (en) 2009-11-23 2011-05-26 Pfizer Inc. Imidazo-pyrazoles as gpr119 inhibitors
US8476225B2 (en) 2009-12-04 2013-07-02 Gilead Sciences, Inc. Antiviral compounds
US8815881B2 (en) 2010-08-09 2014-08-26 Hoffmann-La Roche Inc. 1,4,5,6-tetrahydro-pyrimidin-2-ylamine compounds
CN103124722B (zh) * 2010-09-22 2014-11-12 三井化学Agro株式会社 具有含氟氨基甲酸酯基的氨基酸酰胺衍生物的制造方法、其制造中间体、及乙二胺衍生物的制造方法
WO2012047764A1 (en) * 2010-10-04 2012-04-12 Intermune, Inc. Therapeutic antiviral peptides
CA2822037A1 (en) 2010-12-20 2012-06-28 Gilead Sciences, Inc. Methods for treating hcv
EP2658858A4 (en) * 2010-12-30 2014-06-25 Enanta Pharm Inc MACROCYCLIC INHIBITORS OF HEPATITIS C SERINE PROTEASE PHENANTHRIDINE
WO2012092409A2 (en) 2010-12-30 2012-07-05 Enanta Phararmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
WO2012109398A1 (en) 2011-02-10 2012-08-16 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9540343B2 (en) 2011-07-06 2017-01-10 Gilead Sciences, Inc. Compounds for the treatment of HIV
MD4589C1 (ro) 2011-09-16 2019-03-31 Gilead Pharmasset Llc Compoziţie farmaceutică cu conţinut de sofosbuvir şi utilizarea acesteia în tratamentul hepatitei virale C
US9089574B2 (en) 2011-11-30 2015-07-28 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
US20140100364A1 (en) 2012-10-08 2014-04-10 Abbvie Inc. Compounds Useful For Making HCV Protease Inhibitors
PT2909205T (pt) * 2012-10-19 2017-02-06 Bristol Myers Squibb Co Derivados de carbamato de hexadecahidrociclopropa(e)pirrolo(1,2- a)(1,4)diazaciclopentadecinilo substituídos com 9-metilo como inibidores da protease não estrutural 3 (ns3) para o tratamento de infeções por vírus da hepatite c
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102937580B (zh) * 2012-11-02 2015-09-02 天津科技大学 食用油脂中缩水甘油酯的检测方法
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
ES2642265T3 (es) * 2013-01-09 2017-11-16 Gilead Sciences, Inc. Compuestos terapéuticos para el tratamiento de infecciones virales
NZ625087A (en) 2013-01-31 2017-05-26 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
JP6342922B2 (ja) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
KR20150131244A (ko) * 2013-03-13 2015-11-24 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스테이플드 및 스티치드 폴리펩티드 및 그의 용도
CA2902569A1 (en) 2013-03-15 2014-09-18 Gilead Sciences, Inc. Inhibitors of hepatitis c virus
EP3019172B1 (en) * 2013-07-11 2019-09-25 Evestra, Inc. Pro-drug forming compounds
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
CN105504007B (zh) * 2014-10-14 2021-03-16 中国药科大学 氨基磷酸酯衍生物、其制备方法及其在制药中的用途
DK3236972T3 (en) 2014-12-26 2021-10-04 Univ Emory Antivirale N4-hydroxycytidin-derivativer
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
MX2018014377A (es) 2016-05-27 2019-03-14 Gilead Sciences Inc Metodos para tratar infecciones por virus de hepatitis b usando inhibidores de proteina no estructural 5a (ns5a), proteina no estructural 5b (ns5b) o proteina no estructural 3 (ns3).
US9957233B1 (en) 2016-08-05 2018-05-01 Calitor Sciences, Llc Process for preparing substituted quinolin-4-ol compounds
HUE063811T2 (hu) 2016-08-19 2024-02-28 Gilead Sciences Inc HIV-vírus-fertõzés megelõzõ vagy terápiás kezelésére alkalmas terápiás vegyületek
TW202024061A (zh) 2017-08-17 2020-07-01 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
US10624903B2 (en) 2017-10-19 2020-04-21 Evestra, Inc. Longer-acting progestin prodrug contraceptives
SG11202004403QA (en) 2017-12-07 2020-06-29 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
KR102587510B1 (ko) 2018-02-15 2023-10-11 길리애드 사이언시즈, 인코포레이티드 피리딘 유도체 및 hiv 감염을 치료하기 위한 그의 용도
WO2019161280A1 (en) 2018-02-16 2019-08-22 Gilead Sciences, Inc. Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
CA3216031A1 (en) 2018-07-16 2020-01-23 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
CN111056889B (zh) * 2019-11-22 2022-01-11 华东师范大学 一类n-烷基/n-芳基硫代酰胺衍生物及其合成方法和应用
KR20220106165A (ko) 2019-11-26 2022-07-28 길리애드 사이언시즈, 인코포레이티드 Hiv의 예방을 위한 캡시드 억제제
EP4172157A1 (en) 2020-06-25 2023-05-03 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
CN112961106A (zh) * 2021-03-13 2021-06-15 德州学院 一种4-羟基-6氯喹啉合成新工艺
TW202337439A (zh) 2021-12-03 2023-10-01 美商基利科學股份有限公司 用於ｈｉｖ病毒感染之治療性化合物

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610054A (en) 1992-05-14 1997-03-11 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecule targeted against Hepatitis C virus
MY147327A (en) 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
GB9517022D0 (en) 1995-08-19 1995-10-25 Glaxo Group Ltd Medicaments
US5633388A (en) 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
CA2254122A1 (en) 1996-05-10 1997-11-20 Schering Corporation Synthetic inhibitors of hepatitis c virus ns3 protease
BR9712544B1 (pt) 1996-10-18 2013-10-22 Inibidores de proteases de serina, composição farmacêutica compreendendo os mesmos e seus usos
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
AU7127298A (en) 1997-04-14 1998-11-11 Emory University Serine protease inhibitors
GB9707659D0 (en) 1997-04-16 1997-06-04 Peptide Therapeutics Ltd Hepatitis C NS3 Protease inhibitors
AU757783B2 (en) 1997-08-11 2003-03-06 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptides
EP1012180B1 (en) 1997-08-11 2004-12-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptide analogues
IT1299134B1 (it) 1998-02-02 2000-02-29 Angeletti P Ist Richerche Bio Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi
WO1999050230A1 (en) 1998-03-31 1999-10-07 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
WO2000006529A1 (en) 1998-07-27 2000-02-10 Istituto Di Ricerche Di Biologia Molecolare P Angeletti S.P.A. Diketoacid-derivatives as inhibitors of polymerases
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
KR20010099623A (ko) 1998-08-21 2001-11-09 비로파마 인코포레이티드 바이러스 감염 및 관련 질병을 치료 또는 예방하는화합물, 조성물 및 방법
BR9913406A (pt) 1998-09-04 2002-01-29 Viropharma Inc Processo de tratamento de infecção causada por pelo menos um vìrus da famìlia flaviviridae e de doença associada com a citada infecção em um hospedeiro vivo possuindo a citada infecção
EP1115286A4 (en) 1998-09-25 2003-07-23 Viropharma Inc METHOD FOR TREATING AND PREVENTING VIRAL INFECTIONS AND DISEASES RELATED TO THEM
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6566365B1 (en) 1999-11-04 2003-05-20 Biochem Pharma Inc. Method for the treatment of Flaviviridea viral infection using nucleoside analogues
ID30204A (id) 1999-12-27 2001-11-15 Japan Tobacco Inc Senyawa-senyawa cincin terfusi dan penggunaannya sebagai obat
AU2001261377A1 (en) 2000-05-10 2001-11-20 Smith Kline Beecham Corporation Novel anti-infectives
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
BR0115447A (pt) 2000-11-20 2005-10-18 Bristol Myers Squibb Co Inibidores de tripeptìdeo de hepatite c
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
CA2369711A1 (en) 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
CA2369970A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
CA2370396A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US6828301B2 (en) 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
ATE503764T1 (de) 2002-05-20 2011-04-15 Bristol Myers Squibb Co Inhibitoren des hepatitis-c-virus
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
ATE481106T1 (de) 2002-05-20 2010-10-15 Bristol Myers Squibb Co Heterocyclische sulfonamid-hepatitis-c-virus- hemmer
AU2003301959A1 (en) 2002-05-20 2004-06-03 Bristol-Myers Squibb Company Substituted cycloalkyl p1' hepatitis c virus inhibitors
CN1771050A (zh) 2003-02-07 2006-05-10 益安药业 丙型肝炎丝氨酸蛋白酶的大环抑制剂
DE602004029866D1 (de) 2003-03-05 2010-12-16 Boehringer Ingelheim Pharma Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
CA2516016C (en) 2003-03-05 2012-05-29 Boehringer Ingelheim International Gmbh Hepatitis c inhibiting compounds
US7148347B2 (en) 2003-04-10 2006-12-12 Boehringer Ingelheim International Gmbh Process for preparing macrocyclic compounds
WO2004094452A2 (en) * 2003-04-16 2004-11-04 Bristol-Myers Squibb Company Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus
JP4778893B2 (ja) 2003-04-18 2011-09-21 エナンタ ファーマシューティカルズ インコーポレイテッド キノキサリニル大環状のｃ型肝炎セリンプロテアーゼ阻害剤
CN1791599A (zh) 2003-05-21 2006-06-21 贝林格尔.英格海姆国际有限公司 丙型肝炎抑制剂化合物
WO2004113365A2 (en) 2003-06-05 2004-12-29 Enanta Pharmaceuticals, Inc. Hepatitis c serine protease tri-peptide inhibitors
US7125845B2 (en) 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
RS20060259A (en) 2003-10-14 2008-08-07 Intermune Inc., Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
US7132504B2 (en) * 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
ES2358333T3 (es) * 2004-01-21 2011-05-09 Boehringer Ingelheim International Gmbh Péptidos macrocíclicos con acción contra el virus de la hepatitis c.
EA012389B1 (ru) 2004-03-30 2009-10-30 Интермун, Инк. Макроциклические соединения в качестве ингибиторов вирусной репликации
BRPI0513426A (pt) * 2004-07-16 2007-11-27 Gilead Sciences Inc processo de preparação de amino ácidos úteis na preparação de moduladores de receptores de peptìdeos
CA2573346C (en) 2004-07-20 2011-09-20 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
WO2007001406A2 (en) 2004-10-05 2007-01-04 Chiron Corporation Aryl-containing macrocyclic compounds
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7601686B2 (en) * 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI389908B (zh) * 2005-07-14 2013-03-21 Gilead Sciences Inc 抗病毒化合物類
TW200738742A (en) 2005-07-14 2007-10-16 Gilead Sciences Inc Antiviral compounds
EP2305695A3 (en) * 2005-07-25 2011-07-27 Intermune, Inc. Macrocyclic inhibitors of Hepatitis C virus replication
US7772183B2 (en) * 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Also Published As

Publication number Publication date
JP5465667B2 (ja) 2014-04-09
IL202623A0 (en) 2010-06-30
JP2010532352A (ja) 2010-10-07
WO2009005677A2 (en) 2009-01-08
US20140051626A1 (en) 2014-02-20
CN101801925A (zh) 2010-08-11
EP2162432A2 (en) 2010-03-17
CA2692145C (en) 2015-03-03
TW200914013A (en) 2009-04-01
US8809267B2 (en) 2014-08-19
MX2009013830A (es) 2010-03-01
CA2692145A1 (en) 2009-01-08
AU2008271117A1 (en) 2009-01-08
KR20100038417A (ko) 2010-04-14
CO6251241A2 (es) 2011-02-21
AP2009005073A0 (en) 2009-12-31
JP2013177452A (ja) 2013-09-09
WO2009005677A3 (en) 2009-03-05
SG182979A1 (en) 2012-08-30
US20090186869A1 (en) 2009-07-23
ZA201000614B (en) 2011-11-30
EA200971074A1 (ru) 2010-08-30
ECSP109906A (es) 2010-03-31
AU2008271117B2 (en) 2013-10-24
US8513186B2 (en) 2013-08-20
BRPI0813733A2 (pt) 2019-11-05

Similar Documents

Publication Publication Date Title
AR068794A1 (es) Compuestos antivirales
AR067180A1 (es) Compuestos antivirales
AR061840A1 (es) Compuestos fosfinatos antivirales
AR054837A1 (es) Compuestos inhibidores del virus de la hepatitis c
AR054838A1 (es) Compuestos inhibidores del virus de la hepatitis c
AR080263A1 (es) Inhibidores ns5a de vhc
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
PE20211504A1 (es) Compuestos de anillo fusionado
AR067442A1 (es) Compuestos antivirales
AR081848A1 (es) Inhibidores de la proteina ns5a del vhc
AR084388A1 (es) Compuestos nitrogenados heterociclicos inhibidores de la replicacion del vhc y composiciones farmaceuticas que los contienen
AR074670A1 (es) Inhibidores de la proteasa ns3 del vhc virus de la hepatitis c
ECSP18072109A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo como inhibidores de jak campo de la invención
AR043700A1 (es) Derivados de 3-substituida-4-pirimidona
AR050174A1 (es) Derivados de fosfonatos con actividad antiviral. composiciones farmaceuticas
PE20090042A1 (es) Analogos de ciclopamina
AR056204A1 (es) Derivados de indano como antagonistas de receptores de mch, metodos para su preparacion, intermediarios de sintesis de los mismos, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades relacionadas
AR117139A1 (es) Derivados de piridooxazinona como inhibidores de monoacilglicerol ligasa (magl)
AR057769A1 (es) Pirazolo pirimidinas como inhibidores de map quinasa p38, metodos para utilizarlos y composiciones farmaceuticas
AR052558A1 (es) Derivados de tiazol-4-carboxamida como antagonistas de mglur5
AR084720A1 (es) Inhibidores de anillos fusionados triciclicos de hepatitis c
AR053153A1 (es) Derivados de pirazina -2- carboxamida como antagonistas de mglur5
AR053652A1 (es) Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas
AR030053A1 (es) 1h-pirimido [4,5-d] pirimidin-2-onas y sales, composiciones farmaceuticas, uso para la fabricacion de un medicamento y procedimiento para producirlas
ECSP055815A (es) Composición para el tratamiento de la infección por virus flaviviridae

Legal Events

Date Code Title Description
FA Abandonment or withdrawal